Life Sciences Takeda and Seagen to Highlight ADCETRIS Combination Data Showing Statistically Significant… AIT News Desk May 27, 2022 – Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs.…